Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Recommendation of “Buy” by Analysts

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has earned a consensus rating of “Buy” from the seven analysts that are covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $11.40.

RVPH has been the subject of a number of analyst reports. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a report on Friday, January 10th. D. Boral Capital reiterated a “buy” rating and issued a $15.00 price objective on shares of Reviva Pharmaceuticals in a report on Tuesday, January 21st. Roth Mkm started coverage on Reviva Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $7.00 target price on the stock. HC Wainwright dropped their price target on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Finally, Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Tang Capital Management LLC bought a new position in Reviva Pharmaceuticals in the fourth quarter worth $308,000. Cornerstone Select Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals in the 4th quarter worth about $32,000. Ameriprise Financial Inc. bought a new position in shares of Reviva Pharmaceuticals in the 4th quarter worth about $84,000. Tower Research Capital LLC TRC lifted its position in Reviva Pharmaceuticals by 848.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock valued at $48,000 after acquiring an additional 23,953 shares during the period. Finally, XTX Topco Ltd bought a new stake in Reviva Pharmaceuticals during the fourth quarter worth about $45,000. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Down 3.5 %

Shares of RVPH opened at $1.09 on Thursday. The stock has a market capitalization of $36.45 million, a P/E ratio of -0.98 and a beta of -0.09. Reviva Pharmaceuticals has a twelve month low of $0.60 and a twelve month high of $4.28. The firm has a fifty day simple moving average of $1.56 and a two-hundred day simple moving average of $1.48.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.